Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide

Epilepsy Research

Volumn 73, Issue 1, 2007, Pages 75-84

  Sobol, Eyal ^a   Yagen, Boris ^a,b   Lamb, John G ^c   White, H Steve ^c   Wlodarczyk, Bogdan J ^d   Finnell, Richard H ^d   Bialer, Meir ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF UTAH   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Anticonvulsant activity; Induction of exencephaly; Mutagenicity; N Methoxy 2,2,3,3 tetramethylcyclopropane carboxamide; Pharmacokinetics; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; N METHOXY 2,2,3,3 TETRAMETHYLCYCLOPROPANE CARBOXAMIDE; PENTETRAZOLE; UNCLASSIFIED DRUG; VALPROIC ACID;

AMES TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG POTENCY; ELECTRIC SHOCK; EXENCEPHALY; FEMALE; FETOTOXICITY; FETUS; HIPPOCAMPUS; MALE; MOUSE; MUTAGENICITY; NEURAL TUBE DEFECT; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTICONVULSANTS; CYCLOPROPANES; FEMALE; MALE; MICE; MUTAGENESIS; NEURAL TUBE DEFECTS; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; VALPROIC ACID;

EID: 33846044344     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2006.08.004     Document Type: Article

References (29)

1. Ames B.N., Lee F.D., and Durston W.E. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc. Natl. Acad. Sci. U.S.A. 70 (1973) 782-786
2. Baillie T. Metabolism of valproate to hepatotoxic intermediates. Pharm. Weekbl. Sci. 14 (1992) 122-125
3. Barton M.E., Klein B.D., Wolf H.H., and White S.H. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 47 (2001) 217-227
4. Blotnik S., Bergman F., and Bialer M. Disposition of valpromide,valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Drug Metab. Dispos. 24 (1996) 560-564
5. Bourgeois F.D.B. Valproic acid: clinical efficacy and use in epilepsy. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott Williams & Wilkins Publishers, New York 808-817
6. Finnell R.H., Bennett G.D., Karras S.B., and Mohl V.K. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-pentenoic acid metabolite. Teratology 38 (1988) 313-320
7. Finnell R.H., Wlodarczyk B.J., Craig J.C., Piedrahita J.A., and Bennett G.D. Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model. Am. J. Med. Genet. 70 (1997) 303-311
8. Hauck R.S., and Nau H. Structural bases of the teratogenic effects of the antiepileptic, valproic acid. 2-n-propyl-4-pentenoic acid, the first structural analogue with significantly higher teratogenic action than VPA. Naturwissenschaften 76 (1989) 528-529
9. Kaneko S., Battino D., Anderman E., Wada K., Kan R., Takeda A., Nakane Y., Ogawa Y., Avanzini G., Fumarola C., Granata T., Molteni F., Pardi G., Minotti L., Canger R., Dansky L., Oguni M., Lopes-Cendas I., Sherwin A., Andermann F., Seni M.H., Okada M., and Teranishi T. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 33 (1999) 145-158
10. Konig A.S., Shenk M., Sick C., Holm E., Heubner C., Weiss A., Konig I., and Hehlmann R. Fatal liver failure associated with valproate therapy in patients with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia 40 (1999) 1036-1040
11. Lindhout D., and Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1 (1986) 1392-1393
12. Loscher W. Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. J. Pharmacol. Exp. Ther. 204 (1978) 255-261
13. Loscher W. Pharmacological effects and mechanisms of action. In: Loscher W. (Ed). Valproate (1999), Birkhauser Verlag, Berlin 8-45
14. Lothman E.W., Salerno R.A., Perlin J.B., and Kaiser D.L. Screening and characterization of antiepileptic drugs with rapidly recurring hippocampal seizures in rats. Epilepsy Res. 2 (1988) 367-379
15. Nau H. Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: the parent drug and not one of the metabolites assayed is implicated as teratogen. Fundam. Appl. Toxicol. 6 (1986) 662-668
16. Nau H., Hauck R.S., and Ehlers K. Valproic acid induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. 69 (1991) 310-321
17. Okada A., Kurithara H., Aoki Y., Bialer M., and Fujiwara M. Amidic modification of valproic acid reduces skeletal teratogenicity in mice. Birth Defects Res. (Part B) 71 (2004) 47-53
18. Okada A., Onishi Y., Aoki Y., Yagen B., Sobol E., Bialer M., and Fujiwara M. Teratology study of tetramethylcyclopropyl amide analogues of valproic acid in mice. Birth Defects Res. (Part B) 77 (2006) 227-233
19. Rettie A.E., Rettenmeir A.W., Howald W.N., and Baillie T.A. Cytochrome P450 catalyzed formation of 4-ene-VPA, a toxic metabolite of valproic acid. Science 235 (1987) 890-893
20. Rogawski M.A. Principles of antiepileptic drug action. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott Williams & Wilkins Publishers, New York 3-22
21. Silberstein D.S. Valproic acid: clinical efficacy and use in other neurological disorders. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott Williams & Wilkins Publishers, New York 818-827
22. Shah V.P., Midha K.M., Findlay J.W.A., Hill H.M., Hulse J.D., McGilvelli I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., and Yakobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17 (2000) 1551-1557
23. ss for drugs exhibiting different two-compartment disposition profiles. Biopharm. Drug Dispos. 26 (2005) 51-58
24. Sobol E., Bialer M., and Yagen B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug: valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J. Med. Chem. 47 (2004) 4316-4326
25. Sobol E., Yagen B., Winkler I., Britzi M., Gibson D., and Bialer M. Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethylcyclopropanecarbonylurea, in rats. Drug Metab. Dispos. 33 (2005) 1538-1546
26. Swann C.A. Valproic acid: clinical efficacy and use in psychiatric disorders. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott Williams & Wilkins Publishers, New York 828-836
27. White H.S., Woodhead J.H., Wilcox K.S., Stables J.P., Kupferberg H.J., and Wolf H.H. Discovery and preclinical development of antiepileptic drugs. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs (2002), Lippincott Williams & Wilkins Publishers, New York 36-48
28. Winkler I., Sobol E., Yagen B., Steinman A., Devor M., and Bialer M. Efficacy of antiepileptic tetramethylcyclopropyl analogs of valproic acid amides in a rat model for Neuropathic pain. Neurophamacology 49 (2005) 1110-1120
29. Zimmerman H.J., and Ishak K.G. Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 2 (1982) 591-597